AI is driving real change, but bubble concerns are growing. Investors must balance exposure to AI with broader opportunities and enduring risks in 2026.
Tune in to hear how Eli Lilly’s groundbreaking GLP-1 therapies could reduce chronic disease and improve longevity worldwide. Eric also explores Eli Lilly’s newly announced partnership with the U.S. government, and Lilly’s commitment to expanding global drug access, scaling manufacturing to meet demand, and harnessing the power of innovation and AI to transform health care.
Market shifts. Global news. Our experts distill the latest movements in the financial world into actionable insights.
Work together with a leading active manager to help bolster clients outcomes.
Get insights into key trends.
Find a variety of programs to help take your portfolios and your practice to the next level.
Important Information
*As of September 30, 2025. Firmwide Assets Under Management includes assets managed by T. Rowe Price Associates, Inc., and its investment advisory affliciates.
Assets under management are calculated in US dollars and converted to Canadian dollars using an exchange rate determined by an independent third party.
202508-4661260